Breast Cancer: Lourdes's Survivor Story

Patient Info: Lourdes del Río, Female

Biomarkers: Oncotype test performed; score/result not reported

As of May 2025, Lourdes described herself as cancer-free and 100% healthy, with a mammogram and ultrasound from the previous day coming out perfect.

YouTube (ES search)Read more →

Stage IA ER/PR-positive breast cancer in SLE: arm-behind-back radiation after lumpectomy

Patient Info: Anonymized, Female, 40s | Stage I

Biomarkers: ER >95%; PR >95%; HER2 1+; Ki-67 23%; no BRCA1/2 variants identified

As of April 2025, 15 months after 3D conformal radiotherapy, she had no local recurrence, no distant metastasis, and no radiation pneumonitis.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Brain and Leptomeningeal Metastases Responding to Intrathecal Treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain, leptomeninges

More than 5 years after her September 2019 diagnosis, neurological symptoms had resolved, cerebrospinal fluid remained negative for tumor cells, and maintenance treatment was continuing in February 2025.

PubMed CentralRead more →

Breast Cancer in a Woman Carrying Both BRCA1 and BRCA2 Mutations

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER-positive, PR-positive, HER2-negative, BRCA1 pathogenic variant, BRCA2 pathogenic variant

Remained free of recurrence 17 months after treatment.

PubMed CentralRead more →

Primary neuroendocrine breast tumor: disease-free 5 years after mastectomy and tamoxifen

Patient Info: Anonymized, Female, 50s

Biomarkers: Neuroendocrine breast tumor: ER/PR positive, HER2 negative

As of April 2025, she had remained disease-free for 5 years after mastectomy, negative sentinel lymph node biopsy, and tamoxifen 20 mg once daily.

PubMed CentralRead more →

Stage IIA ER-positive breast cancer with axillary tuberculosis: no metabolically active disease after treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER 78% positive; PR-negative; HER2/neu-negative; Ki-67 21%; Luminal A subtype

As of April 2025, follow-up PET-CT showed no metabolically active disease after mastectomy, adjuvant anthracycline-based chemotherapy, letrozole, and 6 months of anti-tuberculosis therapy.

PubMed CentralRead more →

Metaplastic triple-negative breast cancer: near-complete response to taxane/carboplatin before surgery

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated, triple negative

As of April 2025, imaging after taxane/carboplatin showed a near-complete morpho-metabolic response in the right breast and major reduction of axillary nodal disease, followed by surgery and adjuvant chemotherapy/radiotherapy.

PubMed CentralRead more →

Stage I HR-Positive Invasive Lobular Carcinoma: Mandy's Patient Story

Patient Info: Mandy, Female, 40s | Stage I

Biomarkers: ER-positive; PR-positive; low Oncotype score; genetic testing negative for 70 cancer-causing genes

As of April 2025, Mandy was about 10 months after bilateral mastectomy for Stage IA ER-positive, PR-positive ILC, had a low Oncotype score, was planning several years of tamoxifen, and was still in reconstruction.

Lobular Breast Cancer AllianceRead more →

HER2-amplified primary mucinous cystadenocarcinoma of the breast: surgery and adjuvant treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: HER2-amplified / HER2 3+; ER/PR-negative; Ki-67 ~50%; p53 high; microsatellite stable. No clinically significant inherited mutation reported.

As of November 2024, she had more than 104 months of disease-free survival after breast-conserving surgery, sentinel lymph node biopsy, EC-T chemotherapy, and radiotherapy for Stage IIA HER2-amplified primary mucinous cystadenocarcinoma of the breast.

PubMed CentralRead more →

Stable Metastatic Breast Cancer During Treatment With a CDK4/6 Inhibitor and Fulvestrant

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver

Metastatic breast cancer remained stable after 18 months of tiremciclib and fulvestrant.

PubMed CentralRead more →

Stage 0 Invasive Lobular Carcinoma: Kathleen's Survivor Story

Patient Info: Kathleen, Female | Stage 0

Kathleen completed surgery-focused treatment for DCIS with a very small invasive lobular component. No chemotherapy was needed, endocrine therapy was discussed but not required, and she continued imaging surveillance and advocacy in the flat community.

The Patient StoryRead more →

Early-stage mixed breast carcinoma found during LGI1 limbic encephalitis workup

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER 95-100% positive; PR 80% positive; HER2-negative

She gradually recovered after immunotherapy for limbic encephalitis and excision of the early-stage breast tumor, and had returned to part-time work 12 months after discharge.

PubMed CentralRead more →

Breast cancer linked to a rare kidney condition believed to be cancer-related

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2 score 1+; Ki-67 5-10%

At the latest follow-up, she had no local or distant breast-cancer recurrence and maintained excellent performance status.

PubMed CentralRead more →

Lung inflammation from pembrolizumab immunotherapy returned months after stopping treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: Estrogen receptor-negative; progesterone receptor-negative; HER2-negative

Surgery confirmed a pathologic complete response, and she remained in breast-cancer remission during routine follow-up after treatment for recurrent pembrolizumab-related pneumonitis.

PubMed CentralRead more →

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed CentralRead more →

HER2-positive breast cancer with brain metastases: responding well to T-DXd

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive / HER2 IHC 3+

Metastatic Site: brain (left cerebellum, left frontal lobe, medulla)

After 14 months and 19 doses of T-DXd, brain metastases remained controlled with no symptomatic or radiological relapse and no severe T-DXd-related adverse events.

PubMed CentralRead more →

HER2-Positive Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-negative, PR-negative, HER2-positive

Under surveillance with no evidence of breast-cancer recurrence for 2 years.

PubMed CentralRead more →

HER2-Positive Invasive Ductal Breast Cancer Treated After Chemotherapy-Related Hemorrhagic Cystitis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive, HER2-positive

Under surveillance for 2 years with no signs of malignancy.

PubMed CentralRead more →

Ductal Carcinoma In Situ With Persistent Vaccine-Related Lymph Node Swelling

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive, PR-positive

Recovered uneventfully after mastectomy, with no additional cancer treatment given.

PubMed CentralRead more →

Bilateral inflammatory breast cancer treated with pembrolizumab and surgery

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Bilateral breast cancers had different biology: right side ER/PR-positive and HER2 FISH-negative; left side triple-negative/HER2 1+.

As of March 2025, she had no recurrence 6 months after bilateral mastectomy, bilateral axillary lymph node dissection, thoracoabdominal flap closure, and planned postmastectomy radiation for Stage IIIC bilateral inflammatory breast cancer.

PubMed CentralRead more →

Right Stage IIB ER/PR-positive breast cancer with left epithelioid MPNST: no recurrence after surgery

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Right breast cancer was ER/PR-positive, HER2-negative/1+

As of March 2025, 3 years after bilateral mastectomy, there was no recurrence of the right breast cancer or the left epithelioid malignant peripheral nerve sheath tumor; she remained on anastrozole for the right breast cancer.

PubMed CentralRead more →

Left breast epithelioid MPNST with concurrent right breast cancer: no recurrence after surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Left MPNST markers included S100 and SOX10 positivity. Right breast cancer was ER/PR-positive, HER2-negative/1+

As of March 2025, 3 years after bilateral mastectomy, there was no recurrence of the left epithelioid MPNST or the concurrent right breast invasive ductal carcinoma.

PubMed CentralRead more →

Breast Cancer: Tia's Patient Story

Patient Info: Tia

After breast cancer surgery, Tia was active and focused on restoring shoulder mobility and managing early lymphedema symptoms.

Dana-FarberRead more →

Breast Cancer: Erica's Survivor Story

Patient Info: Erica Deligne, Female

As of March 2025, Erica Deligne was a breast cancer survivor and style advocate helping people understand aesthetic flat closure and post-surgery confidence.